1. Home
  2. CACI vs MRNA Comparison

CACI vs MRNA Comparison

Compare CACI & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CACI International Inc.

CACI

CACI International Inc.

HOLD

Current Price

$640.34

Market Cap

12.9B

Sector

Technology

ML Signal

HOLD

Logo Moderna Inc.

MRNA

Moderna Inc.

HOLD

Current Price

$45.17

Market Cap

11.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CACI
MRNA
Founded
1962
2010
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9B
11.5B
IPO Year
1979
2018

Fundamental Metrics

Financial Performance
Metric
CACI
MRNA
Price
$640.34
$45.17
Analyst Decision
Buy
Hold
Analyst Count
13
13
Target Price
$648.18
$32.75
AVG Volume (30 Days)
327.9K
14.2M
Earning Date
01-21-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
9.49
N/A
EPS
23.34
N/A
Revenue
$8,978,846,000.00
$2,232,000,000.00
Revenue This Year
$11.18
N/A
Revenue Next Year
$7.36
$3.18
P/E Ratio
$27.55
N/A
Revenue Growth
10.41
N/A
52 Week Low
$318.60
$22.28
52 Week High
$683.50
$55.20

Technical Indicators

Market Signals
Indicator
CACI
MRNA
Relative Strength Index (RSI) 65.50 63.48
Support Level $623.69 $39.21
Resistance Level $683.50 $51.18
Average True Range (ATR) 24.18 3.33
MACD 4.26 0.46
Stochastic Oscillator 61.13 56.37

Price Performance

Historical Comparison
CACI
MRNA

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: